New research reveals that individuals who come off new slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass far faster than those who end conventional diet and exercise regimens.
Findings released in a prominent health publication shows that while obese people frequently drop substantial amounts of their body weight while on the medication, the weight comes back at an estimated rate of nearly a kilo each month after stopping.
"Individuals using these medications must be informed of the potential of rapid rebound weight gain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to pre-treatment mass within about one and a half years.
Analyzing Treatments
The research, which examined 37 of studies involving over 9,000 of participants, contrasted the outcomes of these new drugs with conventional dieting.
The team emphasize that individuals who shed pounds through dieting usually have a less rapid weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Fast Rebound
Nutrition scientists believe the mechanism of the drugs explains the accelerated regain.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of the hormone concentrations far above than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' leads to hunger is uncontrolled, making overeating a significant risk."
A Lifelong Issue?
Health authorities recommend the injections for people with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians argue that, due to the high risk of weight regain, the treatment is often long-term.
This opinion is echoed by drug manufacturers, who note that the results "underscore the long-term character of excess weight," similar to managing diseases like high blood pressure.
Patient Experiences
Users who have stopped the medication explain a intense resurgence of appetite.
"It felt as if a trigger activating and you become extremely hungry," said a patient.
This challenge is compounded if individuals have not developed lasting dietary or behavioural changes during therapy.
Growing Use
Survey data show that a significant number of people in the UK have used these injections in the past year, with interest being substantial.
- Use is more common among women than men.
- The 40s and 50s age group shows the highest usage rates.
- Many access the medications through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while the jabs are potent agents for shedding pounds, they are not a permanent cure and maintained weight loss relies on integrated lifestyle support.
